Fundació Sant Joan de Déu   Report issue

Foundation Phase 1 Phase 2 Phase 3 Phase 4
Founded: Barcelona Spain (2002)

Organization Overview

First Clinical Trial
2004
NCT01041092
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Fundació Sant Joan de Déu

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aspergillosis (Phase 2)

Fetal Growth Retardation (Phase 3)

Glioma (Phase 2)

Invasive Pulmonary Aspergillosis (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myeloid (Phase 2)

Multiple Organ Failure (Phase 4)

Neoplasm, Residual (Phase 2)

Neuroblastoma (Phase 2)

Obesity (Phase 2)

Overweight (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Pulmonary Aspergillosis (Phase 2)

Retinoblastoma (Phase 2)

Schizophrenia (Phase 4)

Scoliosis (Phase 2)

Weight Loss (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 18
  • # of Trial APIs: 26